Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Breast Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 4/21/2016 |
| Start Date: | August 2012 |
Amino Acid Transport Imaging of Breast Carcinoma Via Anti-3-[18F]FACBC PET-CT: A Pilot Study
Breast carcinoma is the most frequent cancer in women, affecting an estimated 207,090 in
2010 leading to 39,840 cancer related deaths.
Fludeoxyglucose F 18 Injection (FDG) Positron Emission Tomography, (PET) or PET-CT has
become the a standard method for isolating the tumor. However, FDG is insensitive in small
breast tumors and certain histologic types such as lobular, certain types of breast
carcinoma. In addition, FDG uptake can be nonspecific since inflammatory some benign lesions
may also evidence have accumulation of this radiotracer. Hence there is a need for a
tracer/imaging tool that increases the ability to characterize detect breast carcinoma and
to detect locoregional spread, as well as monitor therapeutic treatment response.
anti-3-[18F]. anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (FACBC) is an amino
acid based PET radiotracer which has shown utility in detecting a variety of tumors. In cell
culture experiments,FACBC has shown uptake in the breast tumor cell line.
The primary aim of this study is to determine if FACBC PET-CT demonstrates uptake within
breast carcinoma (primary site and/or locoregional lymph nodes) and to study uptake kinetics
via time-activity curves from dynamic imaging characteristics. The investigators will enroll
12 patients who have a breast mass or masses and/or lymph nodes naïve to therapy about to
undergo biopsy or post-biopsy pre-therapy. All patients will undergo standard of care
imaging as appropriate such as mammography, ultrasound, MR, and/or FDG PET-CT scanning. The
investigators will then compare findings to determine if this radiotracer is worthy of
further study in a more comprehensive experiment.
2010 leading to 39,840 cancer related deaths.
Fludeoxyglucose F 18 Injection (FDG) Positron Emission Tomography, (PET) or PET-CT has
become the a standard method for isolating the tumor. However, FDG is insensitive in small
breast tumors and certain histologic types such as lobular, certain types of breast
carcinoma. In addition, FDG uptake can be nonspecific since inflammatory some benign lesions
may also evidence have accumulation of this radiotracer. Hence there is a need for a
tracer/imaging tool that increases the ability to characterize detect breast carcinoma and
to detect locoregional spread, as well as monitor therapeutic treatment response.
anti-3-[18F]. anti-1-amino-3-[18F]fluorocyclobutyl-1-carboxylic acid (FACBC) is an amino
acid based PET radiotracer which has shown utility in detecting a variety of tumors. In cell
culture experiments,FACBC has shown uptake in the breast tumor cell line.
The primary aim of this study is to determine if FACBC PET-CT demonstrates uptake within
breast carcinoma (primary site and/or locoregional lymph nodes) and to study uptake kinetics
via time-activity curves from dynamic imaging characteristics. The investigators will enroll
12 patients who have a breast mass or masses and/or lymph nodes naïve to therapy about to
undergo biopsy or post-biopsy pre-therapy. All patients will undergo standard of care
imaging as appropriate such as mammography, ultrasound, MR, and/or FDG PET-CT scanning. The
investigators will then compare findings to determine if this radiotracer is worthy of
further study in a more comprehensive experiment.
Inclusion Criteria:
1. Patients must be 18 years of age or older.
2. Patients will have a breast mass and/or lymph nodes naïve to therapy about to undergo
biopsy or post-biopsy pre-therapy. Patients with known or suspected recurrent disease
will be eligible for this protocol.
3. Ability to lie still for PET scanning
4. Patients must be able to provide written informed consent
Exclusion Criteria:
1. Age less than 18.
2. Inability to lie still for PET scanning.
3. Cannot provide written informed consent.
4. Current therapy for breast carcinoma.
5. Positive serum or urine pregnancy test within 24 hours of study.
We found this trial at
1
site
Emory University Emory University, recognized internationally for its outstanding liberal artscolleges, graduate and professional schools,...
Click here to add this to my saved trials
